IGM BIOSCIENCES INC
NASDAQ: IGMS (IGM Biosciences, Inc.)
Last update: 8 hours ago1.18
0.02 (1.72%)
| Previous Close | 1.16 |
| Open | 1.18 |
| Volume | 101,704 |
| Avg. Volume (3M) | 176,220 |
| Market Cap | 70,935,816 |
| Price / Sales | 0.540 |
| Price / Book | 0.760 |
| 52 Weeks Range | |
| Earnings Date | 12 Aug 2025 - 18 Aug 2025 |
| Operating Margin (TTM) | -6,217.44% |
| Diluted EPS (TTM) | -3.27 |
| Quarterly Revenue Growth (YOY) | 0.40% |
| Total Debt/Equity (MRQ) | 6,298.14% |
| Current Ratio (MRQ) | 5.71 |
| Operating Cash Flow (TTM) | -143.10 M |
| Levered Free Cash Flow (TTM) | -75.65 M |
| Return on Assets (TTM) | -36.78% |
| Return on Equity (TTM) | -245.59% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | IGM Biosciences, Inc. | Mixed | Mixed |
AIStockmoo Score
| Value 35% | -2.5 |
| AI Insight info | NA |
| Relative Valuation info | NA |
| Financial Health info | -2.5 |
| Timing 35% | 0.6 |
| AI Technical info | NA |
| Technical Oscillators info | 0.0 |
| Technical Moving Averages info | 1.5 |
| Smart Money 30% | 0.0 |
| Analyst Consensus info | 0.0 |
| Insider Activity info | NA |
| Environment | ×1.21 |
| Macro Environment info | -3.3 |
| Sector vs Market (6M) | -36.3% |
| Pillar Agreement | ×1.06 |
| Not in score | |
| Price Volatility info | -0.6 |
| Final Score | -0.85 |
Select this tab to load the latest available analysis.
|
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 37.57% |
| % Held by Institutions | 47.53% |
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |